Myofibroblasts in end-stage heart failure retain the capacity to return to a less activated state, highlighting their potential as targets for antifibrotic therapy.
May support myofibroblast-targeted antifibrotic therapy in HF; leaves open translation from animal models.
MyoFb in end-stage HF have a variable degree of differentiation and retain the capacity to return to a less activated state, validating the potential for developing antifibrotic therapy targeting MyoFb.
No takes yet. Share an insight, caveat, or question.
Nagaraju et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: